@article{d7e20e4357bf495ebf8bf10b02742767,
title = "Reproductive and Hormonal Factors and Risk of Ovarian Cancer by Tumor Dominance: Results from the Ovarian Cancer Cohort Consortium (OC3)",
abstract = "Background: Laterality of epithelial ovarian tumors may reflect the underlying carcinogenic pathways and origins of tumor cells.Methods: We pooled data from 9 prospective studies participating in the Ovarian Cancer Cohort Consortium. Information on measures of tumor size or tumor dominance was extracted from surgical pathology reports or obtained through cancer registries. We defined dominant tumors as those restricted to one ovary or where the dimension of one ovary was at least twice as large as the other, and nondominant tumors as those with similar dimensions across the two ovaries or peritoneal tumors. Competing risks Cox models were used to examine whether associations with reproductive and hormonal risk factors differed by ovarian tumor dominance.Results: Of 1,058 ovarian cancer cases with tumor dominance information, 401 were left-dominant, 363 were right-dominant, and 294 were nondominant. Parity was more strongly inversely associated with risk of dominant than nondominant ovarian cancer (P-heterogeneity = 0.004). Ever use of oral contraceptives (OC) was associated with lower risk of dominant tumors, but was not associated with nondominant tumors (Pheterogeneity = 0.01). Higher body mass index was associated with higher risk of left-dominant tumors, but not significantly associated with risk of right-dominant or nondominant tumors (P-heterogeneity = 0.08).Conclusions: These data suggest that reproductive and hormonal risk factors appear to have a stronger impact on dominant tumors, which may have an ovarian or endometriosis origin.Impact: Examining the associations of ovarian cancer risk factors by tumor dominance may help elucidate the mechanisms through which these factors influence ovarian cancer risk.",
keywords = "TUBAL INTRAEPITHELIAL CARCINOMA, LEFT LATERAL PREDISPOSITION, SEROUS CARCINOMA, ORIGIN, ENDOMETRIOSIS, PATHOGENESIS, SURROGATE, MODEL, CELL",
author = "Tianyi Huang and Townsend, {Mary K.} and Nicolas Wentzensen and Britton Trabert and Emily White and Arslan, {Alan A.} and Elisabete Weiderpass and Buring, {Julie E.} and Clendenen, {Tess V.} and Giles, {Graham G.} and I-Min Lee and Milne, {Roger L.} and Onland-Moret, {N. Charlotte} and Ulrike Peters and Sandler, {Dale P.} and Schouten, {Leo J.} and {van den Brandt}, {Piet A.} and Alicja Wolk and Anne Zeleniuch-Jacquotte and Tworoger, {Shelley S.}",
note = "Funding Information: The authors acknowledge the Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital (Boston, MA), as the home of the Nurses{\textquoteright} Health Study. The Nurses{\textquoteright} Health Study would like to thank the following state cancer registries for their assistance: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. This work was supported by Department of Defense Ovarian Cancer Research Program grant W81XWH-12-1-0561 (to S.S. Tworoger). Additional research funding and support included NCI Intramural Research Program; VicHealth and Cancer Council Victoria, and Australian National Health and Medical Research Council grants 209057, 396414, and 1074383 (Melbourne Collaborative Cohort Study); UM1 CA186107, P01 CA87969 (Nurses{\textquoteright} Health Study); UM1 CA176726 (Nurses{\textquoteright} Health Study II); UM1 CA182934, P30 CA016087 and P30 Funding Information: The authors acknowledge the Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital (Boston, MA), as the home of the Nurses? Health Study. The Nurses? Health Study would like to thank the following state cancer registries for their assistance: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. This work was supported by Department of Defense Ovarian Cancer Research Program grant W81XWH-12-1-0561 (to S.S. Tworoger). Additional research funding and support included NCI Intramural Research Program; VicHealth and Cancer Council Victoria, and Australian National Health and Medical Research Council grants 209057, 396414, and 1074383 (Melbourne Collaborative Cohort Study); UM1 CA186107, P01 CA87969 (Nurses? Health Study); UM1 CA176726 (Nurses? Health Study II); UM1 CA182934, P30 CA016087 and P30 ES000260 (NYU Women's Health Study); NIEHS Intramural Research Program (Sisters Study, Project Z01-ES044005 to D.P. Sandler); Swedish Cancer Foundation (Swedish Mammography Cohort); K05CA154337 from the NCI and Office of Dietary Supplements (VITamins And Lifestyle Cohort); and CA047988, HL043851, HL080467, HL099355, and CA182913 (Women's Health Study). Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",
year = "2020",
month = jan,
doi = "10.1158/1055-9965.EPI-19-0734",
language = "English",
volume = "29",
pages = "200--207",
journal = "Cancer Epidemiology Biomarkers & Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "1",
}